Frank Fischer

TherOx, Inc. operates as a medical device company which focuses on developing and commercializing therapies to treat ischemic and oxygen deprived tissue. Its SSO2 therapy consists of TherOx DownStream system, a mobile hardware device that interfaces with the TherOx DownStream Cartridge that controls cartridge operation wherein SSO2 solution is created and mixed with the patient's blood to create superoxygenated blood for delivery to the coronary arteries. The company was founded by David B. Musket, Paul J. Zalesky and J. Richard Spears in 1994 and is headquartered in Irvine, CA.

Aruene Corp. develops portable, non-invasive Transcranial Magnetic Stimulation (TMS) devices for treatment of migraine. It offers SpringTMS, a transcranial magnetic stimulation device for the acute treatment of pain associated with migraine headache with aura. The company was founded by Robert E. Fischell and David R. Fischell in 2002 and is headquartered in Baltimore, MD.

Aphelion Capital LLC (Aphelion Capital) is a venture capital firm founded in 2005 by Ned Scheetz and Rodney Altman. The firm is headquartered in Mill Valley, California.

Epilepsy Foundation provides welfare services. It offers therapies to stop seizures, wellness institute and legal issue services. The company was founded in 1967 and is headquartered in Landover, MD.

Leptos is developing a proprietary neuromodulation therapy for chronic obesity. The treatment, delivered via a pacemaker-type device, involves electrical activation of a specific nerve in the autonomic nervous system. They believe that this therapy may offer an effective minimally invasive, reversible surgical option for people suffering from chronic obesity. As yet, the Leptos therapy is not approved for sale in the United States and is limited to investigational use.

Avertix Medical Systems, Inc. develops and markets cardiac medical devices. Its product allows to reduce time to treatment and minimize heart muscle damage The company was founded by Robert E. Fischell, Tim A. Fischell and David R. Fischell in 2001 and is headquartered in Shrewsbury, NJ.